Rash Due to Epidermal Growth Factor Receptor Inhibitors
Conditions
Keywords
EGFRI, Epidermal Growth Factor Receptor Inhibition, Skin toxicity, Topical, Doxycycline, Foam, Phase II, Cetuximab, Panitumumab, Vectibix, Erbitux, Rash
Brief summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of FDX104 Antibiotic Foam in the prevention of EGFRI skin toxicity in cancer patients receiving Cetuximab or Panitumumab.
Detailed description
This is a phase II multicenter, randomized, double blind, vehicle controlled clinical study to evaluate the safety, tolerability and efficacy of Doxycycline Foam 4% for the prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects with Cancer Receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis. The study consists of a screening visit, a treatment period where patients will be treated topically on the face twice daily for 5 weeks. A post-treatment follow up visit (4 weeks after end of treatment), will be performed only for subjects who have experienced unresolved possibly-related or related adverse events at the end of the treatment. Seven days after randomization and study drug initiation, subjects will start their EGFRI treatment.
Interventions
DRUGFDX104 (4% Doxycycline)
FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
Sponsors
Vyne Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years and older 2. Subjects with any cancer receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis. 3. Scheduled to start Cetuximab or Panitumumab treatment; 4. Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or with a negative subunit hCG pregnancy test immediately prior to study entry. 5. Able to understand and provide signed informed consent. 6. Ability to reliably apply topical FDX104 and vehicle twice a day to the appropriate part of the face 7. Willingness to minimize sun exposure for 5 weeks from randomization 8. ECOG performance status 0-2.
Exclusion criteria
1. Prior allergic reaction or severe intolerance to Doxcycycline and/or other tetracyclines. 2. Prior allergic reaction or severe intolerance to soy or coconut oil 3. Cutaneous metastases on the face or might spread to the face. 4. The presence of any active skin disease (e.g., eczema), tattoos or other problems at application site, (i.e., located on the face) that, in the investigator's opinion, could confound the evaluation of the rash or make topical application unacceptable 5. Hair on the face (e.g beard) which would interfere with the application of the study drug or its evaluation. 6. ANC \<1,500/mm3 (or\<1.5x109/L), or Platelet count \< 100,000/mm3 (or \<100x109/L) 7. Abnormal renal functions: Serum creatinine \>1.6 mg/dL or 142umol/L (SI units) or calculated estimated creatinine clearance \<40 ml/min1.73 m2 based on Cockcroft and Gault formula. 8. Abnormal hepatic functions: Serum Aspartate transaminase (AST) or alanine tansaminase (ALT) \>5 institutional upper limit of normal (ULN). Or Total billirubin \> 2 x institutional ULN or \>5 x institutional ULN if documented liver metastasis. 9. Any clinically significant safety laboratory results that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study 10. Any clinically significant finding on the physical examination that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study 11. Systemic lupus erythematosus 12. Undergoing any current biological treatment for cancer other than the prescribed EGFRI 13. Treatment with topical antibiotics, anti-acne medication and other topical treatments on the face within 14 days prior to treatment start. Use of topical corticosteroids within 2 weeks prior to baseline; only mild to moderate topical steroids are allowed outside the head and neck area. The area should not exceed 10% of the whole body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed in short term use (≤15 consecutive days). 14. Treatment with systemic antibiotics 7 days prior to treatment start. 15. Known or suspected pregnancy, or lactation or planned pregnancy (females) 16. Previous enrolment in a clinical trial involving investigational drug or a medical device within 30 days before provision of written informed consent for the study 17. Subjects who are mentally or physically unable to comply with all aspects of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To investigate the safety and tolerability of FDX104 in cancer patients receiving EGFRI | 9 weeks | To demonstrate the safety and tolerability of FDX104 in terms of skin tolerability, adverse events, serious adverse events and vital signs in subjects with advanced cancer treated by EGFRI. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Reduction of skin toxicity by FDX104 in cancer patients treated with EGFRI | 9 weeks | Reduction in numbers of papulo-pustular eruptions in the treatment side compared to the placebo treated side and reduction in erythema or edema areas in the treatment side compared to the placebo treated side estimated by the MESTT grading scale developed by the Multinational Association of Supportive Care in Cancer (MASCC) and by visual scale of rash severity (Scope A. scale) |
Countries
Israel
Outcome results
None listed